| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GOLM1 |
| Uniprot No | Q8NBJ4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-401aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSSSRSVDL QTRIMELEGR VRRAAAERGA VELKKNEFQG ELEKQREQLD KIQSSHNFQL ESVNKLYQDE KAVLVNNITT GERLIRVLQD QLKTLQRNYG RLQQDVLQFQ KNQTNLERKF SYDLSQCINQ MKEVKEQCEE RIEEVTKKGN EAVASRDLSE NNDQRQQLQA LSEPQPRLQA AGLPHTEVPQ GKGNVLGNSK SQTPAPSSEV VLDSKRQVEK EETNEIQVVN EEPQRDRLPQ EPGREQVVED RPVGGRGFGG AGELGQTPQV QAALSVSQEN PEMEGPERDQ LVIPDGQEEE QEAAGEGRNQ QKLRGEDDYN MDENEAESET DKQAALAGND RNIDVFNVED QKRDTINLLD QREKRNHTL |
| 预测分子量 | 44 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于GOLM1重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*GOLM1 modulates EGFR/RTK cell-surface recycling to drive hepatocellular carcinoma metastasis*
**作者**：Ye Q. et al.
**摘要**：该研究利用重组GOLM1蛋白验证其在肝癌细胞中的功能，发现GOLM1通过调控EGFR等受体酪氨酸激酶的细胞膜循环，促进肿瘤转移，为肝癌治疗提供新靶点。
---
2. **文献名称**：*Recombinant GOLM1 protein as a novel serum biomarker for hepatocellular carcinoma*
**作者**：Mao Y. et al.
**摘要**：研究通过大肠杆菌表达系统制备重组GOLM1蛋白，并开发ELISA检测方法，证实其在肝癌患者血清中显著高表达，可作为潜在诊断标志物。
---
3. **文献名称**：*GP73 (GOLM1) interacts with ARF4 to promote hepatocellular carcinoma cell proliferation*
**作者**：Liu X. et al.
**摘要**：通过重组GOLM1蛋白的体外结合实验，揭示其与ARF4蛋白相互作用，激活MAPK信号通路，从而驱动肝癌细胞增殖的分子机制。
---
4. **文献名称**：*Engineering and characterization of a truncated GOLM1 variant for targeted therapy studies*
**作者**：Zhang L. et al.
**摘要**：该文献报道了一种截短型重组GOLM1蛋白的构建与功能分析，证明其能竞争性抑制全长GOLM1的促癌活性，为靶向治疗提供实验依据。
---
以上文献均聚焦于GOLM1重组蛋白在癌症机制、诊断及治疗中的应用研究。
GOLM1 (Golgi Membrane Protein 1), also known as GP73. is a type II transmembrane protein predominantly localized in the Golgi apparatus. Initially identified for its role in maintaining Golgi structure and facilitating protein trafficking, GOLM1 has gained significant attention due to its overexpression in various cancers, including hepatocellular carcinoma (HCC), prostate cancer, and lung adenocarcinoma. Its upregulation correlates with tumor progression, metastasis, and poor prognosis, making it a potential diagnostic biomarker and therapeutic target. Notably, GOLM1 levels in serum or tissues are elevated in cancer patients compared to healthy individuals, suggesting its clinical utility in early detection and monitoring.
Recombinant GOLM1 protein is engineered using biotechnology platforms, such as bacterial or mammalian expression systems, to produce purified, functional proteins for research and clinical applications. This involves cloning the GOLM1 gene into expression vectors, optimizing conditions for high-yield production, and employing chromatography techniques for purification. The recombinant protein retains biological activity, enabling studies on its molecular interactions, signaling pathways, and role in oncogenesis. For instance, it is used to develop immunoassays (e.g., ELISA) for detecting GOLM1 autoantibodies in patient samples or to generate antibodies for therapeutic exploration.
Current research focuses on leveraging recombinant GOLM1 to design targeted therapies, including antibody-drug conjugates or vaccines, and to unravel its mechanistic contributions to cancer immune evasion and metastasis. Its dual role as a biomarker and a pathogenic driver underscores its translational relevance in precision oncology.
×
